share_log

NexImmune | DEF 14A: Definitive information statements

NexImmune | DEF 14A: Definitive information statements

NexImmune | DEF 14A：股东委托书决议
美股SEC公告 ·  06/21 07:36
Moomoo AI 已提取核心信息
NexImmune, Inc., a biopharmaceutical company, has announced a Special Meeting of Stockholders to be held virtually on July 11, 2024, to vote on the company's dissolution and subsequent liquidation. The meeting follows a series of adjournments due to insufficient quorum and explores the dissolution as the company's efforts to secure additional financing have been unsuccessful. The Board has recommended the liquidation plan, which includes the sale of common stock and warrants for approximately $3.67 million. The Board believes that alternatives to dissolution are limited and may involve seeking voluntary dissolution later with potentially diminished assets or seeking bankruptcy protection. The company has issued a Series A Preferred Stock to ensure the adoption of the dissolution proposal, assuming the majority of common stock votes are in favor. The Board has unanimously recommended stockholders vote for the dissolution and liquidation plan.
NexImmune, Inc., a biopharmaceutical company, has announced a Special Meeting of Stockholders to be held virtually on July 11, 2024, to vote on the company's dissolution and subsequent liquidation. The meeting follows a series of adjournments due to insufficient quorum and explores the dissolution as the company's efforts to secure additional financing have been unsuccessful. The Board has recommended the liquidation plan, which includes the sale of common stock and warrants for approximately $3.67 million. The Board believes that alternatives to dissolution are limited and may involve seeking voluntary dissolution later with potentially diminished assets or seeking bankruptcy protection. The company has issued a Series A Preferred Stock to ensure the adoption of the dissolution proposal, assuming the majority of common stock votes are in favor. The Board has unanimously recommended stockholders vote for the dissolution and liquidation plan.
生物制药公司NexImmune，Inc.宣布将于2024年7月11日以虚拟方式举行特别股东大会，以就公司解散和随后的清算进行投票。 由于投票人不足而经历了一系列中止后，召开了此次大会，探讨了公司解散的可能性，因为公司获得额外融资的努力没有成功。 董事会已经推荐了清算计划，其中包括以大约3.67百万美元的价格出售普通股和认股权证。 董事会认为，解散的替代方案有限，可能涉及稍后寻求自愿解散，而资产可能会减少或寻求破产保护。 该公司已发行A系列优先股，以确保采用解散方案，假定普通股的多数份额投票赞成。 董事会已一致推荐股东投票支持解散和清算计划。
生物制药公司NexImmune，Inc.宣布将于2024年7月11日以虚拟方式举行特别股东大会，以就公司解散和随后的清算进行投票。 由于投票人不足而经历了一系列中止后，召开了此次大会，探讨了公司解散的可能性，因为公司获得额外融资的努力没有成功。 董事会已经推荐了清算计划，其中包括以大约3.67百万美元的价格出售普通股和认股权证。 董事会认为，解散的替代方案有限，可能涉及稍后寻求自愿解散，而资产可能会减少或寻求破产保护。 该公司已发行A系列优先股，以确保采用解散方案，假定普通股的多数份额投票赞成。 董事会已一致推荐股东投票支持解散和清算计划。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息